On November 8, as it gradually became apparent that Donald J Trump was about to defy the expectations of the world to become the 45th President of the United States, markets in Asia opened and nervous investors promptly began to dump shares.
Pharmaceutical stocks, however, remained strong. While markets in general were not sure what to make of “The Donald,” drug companies had a clear view driven by fears of a tougher regulatory environment and the drug price crackdown promised by Democrat nominee Hillary Clinton.
For pharma companies, the “Trump dump” was to occur later, during a press conference in January, when the soon-to-be-inaugurated President-elect provided the first unambiguous post-election insight into his stance towards the industry.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze